A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
TACROLIMUSTest IMP without active substanceALPN-303 solution for injectionALPN-303 Solution for Injection in Pre-filled PenTACROLIMUSTACROLIMUS
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Proportion of Participants with Complete Clinical Remission Definition 1 (CR1) CR1 [Time Frame: At Week 72]
Endpoint detail
Proportion of Participants with Complete Clinical Remission Definition 2 (CR2). [Time Frame: At Week 72], Proportion of Participants with Overall Clinical Remission (OR). [Time Frame: At Week 72], Safety and tolerability as determined by AEs, clinical laboratory values, standard 12-lead ECGs, and vital signs
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.